Dean Y Maeda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6847647/publications.pdf

Version: 2024-02-01

28 papers	2,034 citations	471509 17 h-index	501196 28 g-index
33 all docs	33 docs citations	33 times ranked	3496 citing authors

#	Article	IF	Citations
1	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discovery, 2022, 12, 47-61.	9.4	58
2	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers, 2021, 13, 968.	3.7	9
3	Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. Nature Communications, 2021, 12, 5024.	12.8	11
4	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical Cancer Research, 2020, 26, 1420-1431.	7.0	151
5	Simultaneous inhibition of CXCR1/2, TGF-Î², and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
6	Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. Journal of Pain, 2019, 20, 1218-1235.	1.4	10
7	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell, 2019, 35, 559-572.e7.	16.8	353
8	Desmetramadol Is Identified as a G-Protein Biased Âμ Opioid Receptor Agonist. Frontiers in Pharmacology, 2019, 10, 1680.	3.5	10
9	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight, 2019, 4, .	5.0	168
10	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight, 2019, 4, .	5.0	113
11	Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature, 2017, 543, 728-732.	27.8	403
12	Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3793-3797.	2.2	12
13	Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2280-2284.	2.2	12
14	Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. Journal of Medicinal Chemistry, 2014, 57, 8378-8397.	6.4	29
15	Intestinal Transport of Aminopterin Enantiomers in Dogs and Humans with Psoriasis Is Stereoselective: Evidence for a Mechanism Involving the Proton-Coupled Folate Transporter. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 696-708.	2.5	20
16	Nicotinamide Glycolates Antagonize CXCR2 Activity through an Intracellular Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 145-152.	2.5	9
17	IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L512-L519.	2.9	30
18	Snap-to-it probes: chelate-constrained nucleobase oligomers with enhanced binding specificity. Nucleic Acids Research, 2008, 36, 3522-3530.	14.5	8

#	Article	IF	Citations
19	Optimization of Bivalent Glutathione S-Transferase Inhibitors by Combinatorial Linker Design. Journal of the American Chemical Society, 2006, 128, 8615-8625.	13.7	23
20	Glutathione S-transferase P1-1 expression modulates sensitivity of human kidney 293 cells to photodynamic therapy with hypericin. Archives of Biochemistry and Biophysics, 2006, 449, 94-103.	3.0	21
21	Bivalent inhibitors of glutathione S-transferase: The effect of spacer length on isozyme selectivity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3780-3783.	2.2	20
22	Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Molecular Pharmaceutics, 2004, 1, 40-48.	4.6	110
23	N-Arylalkylpiperidines as High-Affinity Sigma-1 and Sigma-2 Receptor Ligands: Phenylpropylamines as Potential Leads for Selective Sigma-2 Agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 497-500.	2.2	30
24	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. Journal of Biological Chemistry, 2001, 276, 42639-42644.	3.4	297
25	Studies into the Direct Conversion of Indolomorphinans to their 4-Phenolic Derivatives. Tetrahedron, 2000, 56, 7399-7402.	1.9	4
26	A sigma-1 receptor selective analogue of BD1008. a potential substitute for (+)-opioids in sigma receptor binding assays. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 17-18.	2.2	20
27	Synthesis and Evaluation of Isothiocyanate-Containing Derivatives of the Î´-Opioid Receptor Antagonist Tyr-Tic-Phe-Phe (TIPP) as Potential Affinity Labels for Î´-Opioid Receptors. Journal of Medicinal Chemistry, 2000, 43, 5044-5049.	6.4	15
28	Synthesis and Evaluation of N,N-Dialkyl Enkephalin-Based Affinity Labels for Î´ Opioid Receptors. Journal of Medicinal Chemistry, 2000, 43, 3941-3948.	6.4	19